Trials and TRIPS-ulations: Indian patent law and Novartis ag v. Union of India

When pharmaceutical company Novartis challenged the rejection of its patent application for the leukemia drug Gleevec in Novartis AG v. Union of India, it became the first major legal challenge to India’s newly amended patent law. In 2005, India purportedly made the final changes required to bring its intellectual property laws in compliance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS), the World Trade Organization’s (WTO) minimum standards for intellectual property protection, but its patent law is still fraught with a number of controversial provisions.